×
For best experience we recommend to activate Javascript in your browser.
Recombinant ENPP3 antibody
The Human Monoclonal anti-ENPP3 antibody (Clone Ags-16C3F) (ABIN7676154) specifically detects ENPP3 in FACS, ELISA, BLI, Func and SPR.
The antibody is reactive with Human samples.
Catalog No. ABIN7676154
$294.23
$346.15
save $51.92 (-15 %)
Plus shipping costs $50.00
1 mg ABIN7581380
100 μg ABIN7676154
1 mg ABIN7581380
100 μg ABIN7676154
Delivery in 10 to 11 Business Days
Quick Overview for Recombinant ENPP3 antibody (ABIN7676154)
Target
See all ENPP3 Antibodies
ENPP3
(Ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3))
Antibody Type
Recombinant Antibody
Reactivity
All reactivities for ENPP3 antibodies
Human
Host
All hosts for ENPP3 antibodies
Human
Clonality
All clonalities for ENPP3 antibodies
Monoclonal
Conjugate
All conjugates for ENPP3 antibodies
This ENPP3 antibody is un-conjugated
Application
All applications for ENPP3 antibodies
Flow Cytometry (FACS), ELISA, Bio-Layer Interferometry (BLI), Functional Studies (Func), Surface Plasmon Resonance (SPR)
Clone
Ags-16C3F
Product Details anti-ENPP3 Antibody
(hide)
Expression System
CHO Cells
Purpose
Anti-ENPP3 / CD203c Reference Antibody (Ags-16C3F)
Characteristics
Anti-ENPP3 / CD203c Reference Antibody (Ags-16C3F) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 154.04 kDa.
Purity
>95 %
Isotype
IgG1
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Lyophilized
Concentration
1 mg/mL
Buffer
25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
Storage
4 °C,-80 °C
Storage Comment
+4°C,-80°C
Target Details for ENPP3
(hide)
Target
ENPP3
(Ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3))
Alternative Name
ENPP3
Molecular Weight
154.04 kDa
UniProt
O14638
Pathways
Regulation of Muscle Cell Differentiation , Negative Regulation of Transporter Activity
Recently viewed
(hide)
Chat with us , powered by LiveChat